Design and evaluation of peptide-18-targeted nanoliposomes constructed by poly(2-oxazoline)-DOPE for doxorubicin delivery

References

• Abdelbary, A.A., Abd-Elsalam, W.H., and Al-Mahallawi, A.M., 2019. Fabrication of levofloxacin polyethylene glycol decorated nanoliposomes for enhanced management of acute otitis media: Statistical optimization, trans-tympanic permeation and in vivo evaluation. International journal of pharmaceutics, 559, 201–209.
   PubMed Web of Science ®Google Scholar
• Abdik, E.A., et al., 2019. Suppressive role of boron on adipogenic differentiation and fat deposition in human mesenchymal stem cells. Biological trace element research, 188 (2), 384–392.
   PubMed Web of Science ®Google Scholar
• Accardo, A., and Morelli, G., 2015. Review peptide-targeted liposomes for selective drug delivery: Advantages and problematic issues. Biopolymers, 104 (5), 462–479.
   PubMed Web of Science ®Google Scholar
• Ahmed, S., et al., 2010. Peptide arrays for screening cancer specific peptides. Analytical chemistry, 82 (18), 7533–7541.
   PubMed Web of Science ®Google Scholar
• Aina, O.H., et al., 2007. From combinatorial chemistry to cancer-targeting peptides. Molecular pharmaceutics, 4 (5), 631–651.
   PubMed Web of Science ®Google Scholar
• Askoxylakis, V., et al., 2005. Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clinical cancer research: an official journal of the American association for cancer research, 11 (18), 6705–6712.
   PubMed Web of Science ®Google Scholar
• Askoxylakis, V., et al., 2006. Characterization and development of a peptide (p160) with affinity for neuroblastoma cells. Journal of nuclear medicine: official publication, society of nuclear medicine, 47 (6), 981–988.
   PubMed Web of Science ®Google Scholar
• Barenholz, Y., 2001. Liposome application: problems and prospects. Current opinion in colloid and interface science, 6 (1), 66–77.
   Web of Science ®Google Scholar
• Bozzuto, G., and Molinari, A., 2015. Liposomes as nanomedical devices. International journal of nanomedicine, 10, 975–999.
   PubMed Web of Science ®Google Scholar
• Bugaj, J.E., et al., 2001. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. Journal of biomedical optics, 6 (2), 122–133.
   PubMed Web of Science ®Google Scholar
• Celia, C., et al., 2011. Nanoparticulate devices for brain drug delivery. Medicinal research reviews, 31 (5), 716–756.
   PubMed Web of Science ®Google Scholar
• Chames, P., and Baty, D., 2000. Antibody engineering and its applications in tumor targeting and intracellular immunization. FEMS microbiology letters, 189 (1), 1–8.
   PubMed Web of Science ®Google Scholar
• Charcosset, C., et al., 2015. Preparation of liposomes at large scale using the ethanol injection method: Effect of scale-up and injection devices. Chemical Engineering Research and Design, 94, 508–515.
   Web of Science ®Google Scholar
• de Melo-Diogo, D., et al., 2018. POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells. European journal of pharmaceutics and biopharmaceutics : official journal of arbeitsgemeinschaft fur pharmazeutische verfahrenstechnik e.V, 131, 162–169.
   PubMed Web of Science ®Google Scholar
• Del Vecchio, D.C.A., Li, G., and Wong, A.J., 2012. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Expert review of vaccines, 11 (2), 133–144.
   PubMed Web of Science ®Google Scholar
• Diaby, V., et al., 2015. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast cancer research and treatment, 151 (1), 27–40.
   PubMed Web of Science ®Google Scholar
• Diermeier-Daucher, S., et al., 2011. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors. Cytometry. Part A: the journal of the international society for analytical cytology, 79 (9), 684–693.
   PubMed Web of Science ®Google Scholar
• Fisusi, F.A., and Akala, E.O., 2019. Drug combinations in breast cancer therapy. Pharmaceutical nanotechnology, 7 (1), 3–23.
   PubMedGoogle Scholar
• Gao, N., et al., 2019. pH-responsive dual drug-loaded nanocarriers based on poly (2-ethyl-2-oxazoline) modified black phosphorus nanosheets for cancer chemo/photothermal therapy. Frontiers in pharmacology, 10, 270.
   PubMed Web of Science ®Google Scholar
• Gindy, M.E., Panagiotopoulos, A.Z., and Prud'homme, R.K., 2008. Composite block copolymer stabilized nanoparticles: simultaneous encapsulation of organic actives and inorganic nanostructures. Langmuir: the ACS journal of surfaces and colloids, 24 (1), 83–90.
   PubMed Web of Science ®Google Scholar
• Guillemard, V., and Saragovi, H.U., 2004. Novel approaches for targeted cancer therapy. Current cancer drug targets, 4 (4), 313–326.
   PubMed Web of Science ®Google Scholar
• Gulyuz, S., et al., 2018. In-vitro cytotoxic activities of poly(2-ethyl-2-oxazoline)-based amphiphilic block copolymers prepared by CuAAC click chemistry. Express polymer letters, 12 (2), 146–158.
   Web of Science ®Google Scholar
• Gulyuz, S., et al., 2020. Synthesis, biocompatibility and gene encapsulation of poly(2-ethyl 2-oxazoline)-dioleoyl phosphatidyl ethanolamine (petox-dope) and post-modifications with peptides and fluorescent dye coumarin. International journal of polymeric materials and polymeric biomaterials. DOI: 10.1080/00914037.2020.1767617
   PubMed Web of Science ®Google Scholar
• Hatakeyama, H., Akita, H., and Harashima, H., 2013. The polyethyleneglycol dilemma: advantage and disadvantage of pegylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biological and pharmaceutical bulletin, 36 (6), 892–899.
   PubMed Web of Science ®Google Scholar
• Huang, H., et al., 2010. Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector. Biomaterials, 31 (7), 1830–1838.
   PubMed Web of Science ®Google Scholar
• Hubbell, J.A., and Chilkoti, A., 2012. Chemistry. Nanomaterials for drug delivery. Science (new york, N.Y.), 337 (6092), 303–305.
   PubMed Web of Science ®Google Scholar
• Hwang, M., Moretti, L., and Lu, B., 2009. HSP90 Inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Current medicinal chemistry, 16 (24), 3081–3092.
   PubMed Web of Science ®Google Scholar
• Immordino, M.L., Dosio, F., and Cattel, L., 2006. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International journal of nanomedicine, 1 (3), 297–315.
   PubMed Web of Science ®Google Scholar
• Jungsuwadee, P., 2016. Doxorubicin-induced cardiomyopathy: an update beyond oxidative stress and myocardial cell death. Cardiovascular regenerative medicine, 3, e1127.
   Google Scholar
• Kara, A., et al., 2018. Development of novel self-assembled polymeric micelles from partially hydrolysed poly(2-ethyl-2-oxazoline)-co-PEI-b-PCL block copolymer as non-viral vectors for plasmid DNA in vitro transfection. Artificial cells, nanomedicine, and biotechnology, 46 (sup3), S264–S273.
   PubMed Web of Science ®Google Scholar
• Klibanov, A.L., et al., 1990. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS letters, 268 (1), 235–237.
   PubMed Web of Science ®Google Scholar
• Lewis Phillips, G.D., et al., 2008. Targeting HER2-positive breast cancer with trastuzumab-dm1, an antibody-cytotoxic drug conjugate. Cancer research, 68 (22), 9280–9290.
   PubMed Web of Science ®Google Scholar
• Lorson, T., et al., 2018. Poly(2-oxazoline)s based biomaterials: A comprehensive and critical update. Biomaterials, 178, 204–280.
   PubMed Web of Science ®Google Scholar
• Mathews, A.S., et al., 2013. Peptide modified polymeric micelles specific for breast cancer cells. Bioconjugate chemistry, 24 (4), 560–570.
   PubMed Web of Science ®Google Scholar
• McNeil, S.E., 2016. Evaluation of nanomedicines: stick to the basics. Nature reviews materials, 1 (10), 16073.
   Web of Science ®Google Scholar
• Mochizuki, S., et al., 2013. The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine. Biochimica et biophysica acta, 1828 (2), 412–418.
   PubMed Web of Science ®Google Scholar
• Moghimi, S.M., and Szebeni, J., 2003. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress in lipid research, 42 (6), 463–478.
   PubMed Web of Science ®Google Scholar
• Mufamadi, M.S., et al., 2011. A review on composite liposomal technologies for specialized drug delivery. Journal of drug delivery, 2011, 939851.
   PubMedGoogle Scholar
• Munster, P., et al., 2018. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. British journal of cancer, 119 (9), 1086–1093.
   PubMed Web of Science ®Google Scholar
• Nii, T., and Ishii, F., 2005. Encapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle method. International journal of pharmaceutics, 298 (1), 198–205.
   PubMed Web of Science ®Google Scholar
• Oz, U.C., et al., 2019. Design of colloidally stable and non-toxic petox-based polymersomes for cargo molecule encapsulation. ChemNanoMat., 5 (6), 766–775.
   Web of Science ®Google Scholar
• Paliwal, S.R., et al., 2016. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin. Journal of liposome research, 26 (4), 276–287.
   PubMed Web of Science ®Google Scholar
• Pattni, B.S., Chupin, V.V., and Torchilin, V.P., 2015. New developments in liposomal drug delivery. Chemical reviews, 115 (19), 10938–10966.
   PubMed Web of Science ®Google Scholar
• Perrault, S.D., et al., 2009. Mediating tumor targeting efficiency of nanoparticles through design. Nano letters, 9 (5), 1909–1915.
   PubMed Web of Science ®Google Scholar
• Pippa, N., et al., 2014. The interplay between the rate of release from polymer grafted liposomes and their fractal morphology. International journal of pharmaceutics, 465 (1-2), 63–69.
   PubMed Web of Science ®Google Scholar
• Reynolds, J.G., et al., 2012. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicology and applied pharmacology, 262 (1), 1–10.
   PubMed Web of Science ®Google Scholar
• Ruoslahti, E., Duza, T., and Zhang, L., 2005. Vascular homing peptides with cell-penetrating properties. Current pharmaceutical design, 11 (28), 3655–3660.
   PubMed Web of Science ®Google Scholar
• Sabeti, B., et al., 2014. Development and characterization of liposomal doxorubicin hydrochloride with palm oil. BioMed research international, 2014, 765426.
   PubMed Web of Science ®Google Scholar
• Sadzuka, Y., et al., 2002. Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome. International journal of pharmaceutics, 238, 171–180.
   PubMed Web of Science ®Google Scholar
• Soudy, R., et al., 2011. Proteolytically stable cancer targeting peptides with high affinity for breast cancer cells. Journal of medicinal chemistry, 54 (21), 7523–7534.
   PubMed Web of Science ®Google Scholar
• Soudy, R., et al., 2017. Breast cancer targeting peptide binds keratin 1: a new molecular marker for targeted drug delivery to breast cancer. Molecular pharmaceutics, 14 (3), 593–604.
   PubMed Web of Science ®Google Scholar
• Suk, J.S., et al., 2016. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Advanced drug delivery reviews, 99 (Pt A), 28–51.
   PubMed Web of Science ®Google Scholar
• Sun, H., et al., 2019. A multifunctional liposomal nanoplatform co-delivering hydrophobic and hydrophilic doxorubicin for complete eradication of xenografted tumors. Nanoscale, 11 (38), 17759–17772.
   PubMed Web of Science ®Google Scholar
• Xie, S., et al., 2011. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: Influences of fatty acids. Colloids surface B biointerfaces, 83 (2), 382–387.
   PubMed Web of Science ®Google Scholar
• Xing, J., et al., 2019. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy. International journal of nanomedicine, 14, 5201–5213.
   PubMed Web of Science ®Google Scholar
• Xu, H., et al., 2015. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery. European journal of pharmaceutics and biopharmaceutics: official journal of arbeitsgemeinschaft fur pharmazeutische verfahrenstechnik e.V, 91, 66–74.
   PubMed Web of Science ®Google Scholar
• Yahuafai, J., et al., 2014. Suppression in mice of immunosurveillance against PEGylated liposomes by encapsulated doxorubicin. Journal of controlled release: official journal of the controlled release society, 192, 167–173.
   PubMed Web of Science ®Google Scholar
• Yoon, Y.H., et al., 2019. Enhanced intracellular delivery of bcg cell wall skeleton into bladder cancer cells using liposomes functionalized with folic acid and pep-1 peptide. Pharmaceutics, 11 (12), 652.
   PubMed Web of Science ®Google Scholar
• Zhang, J., Spring, H., and Schwab, M., 2001. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer letters, 171 (2), 153–164.
   PubMed Web of Science ®Google Scholar